Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267


Delayed Quote. Delayed Swiss Exchange - 11/25 07:01:17 am
81.1 CHF   +1.03%
06:06aNOVARTIS AG : UBS reiterates its Buy rating
04:30aNOVARTIS AG : Goldman Sachs remains its Buy rating
11/24GLOBAL MARKETS LIVE: Tesla, Best Buy, Qantas…
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

New $1 billion fund aims to steer antibiotic companies in tough market

07/09/2020 | 09:29am EST
FILE PHOTO: A logo for Pfizer is displayed on a monitor on the floor at the NYSE in New York

By Manas Mishra

Several large drugmakers including Merck & Co Inc and Pfizer Inc on Thursday unveiled a $1 billion (790 million pounds) fund to bolster struggling antibiotic companies and sustain a pipeline for new treatments.

Antibiotic makers have struggled with anemic investment and bankruptcies, even after the approval of new drugs, as fears of drug-resistant microbes force hospitals to adopt a more conservative approach toward such treatments.

Public health authorities have raised alarms about a looming health crisis, saying deaths from antibiotic-resistant bacteria could dwarf that from the COVID-19 pandemic.

The fund, led by the International Federation of Pharmaceutical Manufacturers & Associations, seeks to serve as a temporary solution until new legislation can offer a more permanent fix in the market.

It aims to help shore up investment in smaller biotech companies after several large drugmakers, such as Sanofi SA bowed out of the antibiotics space.

"The fund is being developed to buy time for the future," said Eli Lilly and Co CEO David Ricks. "We are probably buying 4-5 years of time with this initiative."

Other companies participating in the fund include Johnson & Johnson, Novartis and GlaxoSmithKline.

The initiative "gives these biotechs access to the kinds of capabilities that large pharmaceutical companies have, such as manufacturing and regulatory," said Silas Holland, head of external affairs for the fund and director of global public policy at Merck.

An independent scientific panel will review and recommend funding for companies developing promising novel antibiotics, Holland said. The group's goal is to bring two to four new antibiotics to patients within a decade.

(Reporting by Manas Mishra in Bengaluru and Robin Respaut in San Francisco; Editing by Anil D'Silva and Ramakrishnan M.)

© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ELI LILLY AND COMPANY 1.06% 144.9 Delayed Quote.10.25%
GLAXOSMITHKLINE PLC 0.29% 1383.4 Delayed Quote.-22.43%
NOVARTIS AG 0.93% 81.1 Delayed Quote.-12.66%
NOVO NORDISK A/S 0.08% 413 Delayed Quote.6.76%
PFIZER INC. 0.22% 36.6 Delayed Quote.-6.59%
SANOFI 0.84% 84.96 Real-time Quote.-6.04%
All news about NOVARTIS AG
06:06aNOVARTIS AG : UBS reiterates its Buy rating
04:30aNOVARTIS AG : Goldman Sachs remains its Buy rating
11/24GLOBAL MARKETS LIVE: Tesla, Best Buy, Qantas…
11/24NOVARTIS AG : Goldman Sachs reaffirms its Buy rating
11/24NOVARTIS : to Repurchase Up to $2.5 Billion in Shares
11/24NOVARTIS : starts share buyback, highlights product pipeline
11/24NOVARTIS : highlights confidence in growing sales with margin expansion, fueled ..
11/20GLOBAL MARKETS LIVE: Pfizer, General Motors, Alphabet…
11/20NOVARTIS : New data at ASH to reinforce breadth of Novartis hematology portfolio..
11/20Pfizer suffers setback in ENBREL battle of patent infringement claim
More news
Financials (USD)
Sales 2020 49 152 M - -
Net income 2020 8 354 M - -
Net Debt 2020 19 978 M - -
P/E ratio 2020 24,0x
Yield 2020 3,58%
Capitalization 200 B 200 B -
EV / Sales 2020 4,48x
EV / Sales 2021 4,11x
Nbr of Employees 110 000
Free-Float 86,9%
Duration : Period :
Novartis AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 105,85 $
Last Close Price 88,10 $
Spread / Highest target 59,8%
Spread / Average Target 20,1%
Spread / Lowest Target -26,5%
EPS Revisions
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Elizabeth Theophille Chief Technology & Digital Officer
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG-12.66%200 273
JOHNSON & JOHNSON-1.37%378 744
ROCHE HOLDING AG-4.28%281 946
PFIZER INC.-6.59%203 437
MERCK & CO., INC.-11.89%202 757
ABBVIE INC.17.42%183 539